Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis

被引:15
|
作者
Castro, Rodolfo [1 ,2 ]
Perazzo, Hugo [3 ]
Artilles Mello Mendonca de Araujo, Leticia [1 ]
Gutierres, Isabella Goncalves [1 ]
Grinsztejn, Beatriz [3 ]
Veloso, Valdilea G. [3 ]
机构
[1] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, RJ, Brazil
[2] Univ Fed Estado Rio de Janeiro, Inst Saude Colet, Rio De Janeiro, RJ, Brazil
[3] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil
来源
PLOS ONE | 2020年 / 15卷 / 02期
关键词
REAL-WORLD; CARE; SOFOSBUVIR; SAFETY; REGIMENS; THERAPY; PROGRAM;
D O I
10.1371/journal.pone.0229143
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Direct-acting agents (DAAs) for hepatitis C virus (HCV) treatment are safe and highly effective. Few studies described the sustained virologic response rates of treatment conducted by non-specialists. We performed a systematic review and meta-analysis to evaluate the effectiveness of decentralized strategies of HCV treatment with DAAs. PubMed, Embase, Scopus and LILACS were searched until March-2019. Studies were screened by two researchers according to the following inclusion criteria: HCV treatment using DAAs on real-life cohort studies or clinical trials conducted by non-specialized health personnel. The primary endpoint was the sustained virologic response rate at week 12 after the end-of-treatment (SVR12), which is binary at the patient level. Data were extracted in duplicate using electronic-forms and quality appraisal was performed with the NIH Quality Assessment Tool. Heterogeneity was assessed by I-2 statistics. Random-effects meta-analysis models were used for pooling SVR12 rates. Publication bias was assessed using funnel plots. Among the 130 selected studies, nine papers were included for quantitative synthesis. The quality-appraisal was good for two, fair for three and poor for four studies. The pooled relative risk (RR) of SVR12 was not statistically different between decentralized strategy and treatment by specialists [RR = 1.05; 95% confidence interval (95% CI): 0.98-1.1; I-2 = 45% (95% CI: 0-84%), p = 0.145]. SVR12 rate for decentralized HCV treatment was 81% [SVR12 95% CI: 72-89%; I-2 = 93% (95% CI: 88-96%)] and 95% [SVR12 95%CI: 92-98%; I-2 = 77% (95% CI: 52-89%)] with intention to treat analysis and per-protocol analysis, respectively. SVR12 rates using DAAs managed by non-specialized health personnel were satisfactory and similar to those obtained by specialists. This new delivery strategy can improve access to HCV treatment, especially in resource-limited settings.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials
    Pecoraro, Valentina
    Banzi, Rita
    Cariani, Elisabetta
    Chester, Johanna
    Villa, Erica
    D'Amico, Roberto
    Bertele, Vittorio
    Trenti, Tommaso
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 9 (04) : 522 - 538
  • [32] Hepatitis C virus resistance to the new direct-acting antivirals
    Esposito, Isabella
    Trinks, Julieta
    Soriano, Vicente
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (10) : 1197 - 1209
  • [33] Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis
    Lui, Felix H.
    Moosvi, Zain
    Patel, Anish
    Hussain, Samiya
    Duong, Alex
    Duong, Jacqueline
    Nguyen, Douglas L.
    [J]. ANNALS OF GASTROENTEROLOGY, 2020, 33 (03): : 293 - 298
  • [34] Effectiveness of direct-acting antiviral therapy for hepatitis C among people with hepatocellular carcinoma: A systematic review and meta-analysis
    He, S.
    Hajarizadeh, B.
    Lockart, I.
    Alavi, M.
    Danta, M.
    Dore, G.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 71 - 72
  • [35] EFFECTIVENESS AND SAFETY OF DIRECT-ACTING ANTIVIRALS IN PSYCHIATRIC HEPATITIS C VIRUS INFECTED PATIENTS
    Margusino-Framinan, Luis
    Bobadilla-Perez, Eva
    Carlos Yanez-Rubal, Juan
    Prieto-Perez, Andrea
    Cid-Silva, Purificacion
    Rodriguez-Sotelo, Alejandro
    Gimenez-Arufe, Victor
    Quiroga-Fernandez, Candela
    Isabel Sanclaudio-Luhia, Ana
    Novo-Ponte, Ana
    Mena-De-Cea, Alvaro
    Martin-Herranz, Isabel
    Castro-Iglesias, Angeles
    [J]. HEPATOLOGY, 2019, 70 : 966A - 966A
  • [36] Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review
    Ortiz-Paredes, David
    Amoako, Afia
    Ekmekjian, Taline
    Engler, Kim
    Lebouche, Bertrand
    Klein, Marina B.
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [37] Decreased Risk of Hepatocellular Carcinoma Recurrence With Direct-Acting Antivirals for Hepatitis C: A Meta-Analysis
    Lui, Felix
    Hussain, Samiya
    Patel, Anish
    Bechtold, Matthew
    Nguyen, Douglas
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S547 - S548
  • [38] Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis
    Singh, Sonal
    Nautiyal, Amit
    Loke, Yoon K.
    [J]. FRONTLINE GASTROENTEROLOGY, 2018, 9 (04) : 262 - 270
  • [39] Outcomes of direct-acting antivirals in patients with HCV decompensated cirrhosis: a systematic review and meta-analysis
    Jongraksak, Tanawat
    Chuncharunee, Alan
    Intaraprasong, Pongphob
    Tansawet, Amarit
    Thakkinstian, Ammarin
    Sobhonslidsuk, Abhasnee
    [J]. FRONTIERS IN MEDICINE, 2023, 10
  • [40] Comments on Cochrane Review on Direct-Acting Antivirals for Hepatitis C
    Lok, Anna S.
    Chung, Raymond T.
    Vargas, Hugo E.
    Kim, Arthur Y.
    Naggie, Susanna
    Powderly, William G.
    [J]. HEPATOLOGY, 2017, 66 (04) : 1016 - 1019